The "fourteenth five year plan" and the long-term goal outline for 2035 put forward "accelerating the development of biomedicine, biological breeding, biomaterials, bioenergy and other industries, and making the bio economy bigger and stronger". Not long ago, China's first Five-Year Plan for bioeconomy, the 14th five year plan for bioeconomy development, was issued. What is bioeconomy? What areas deserve attention? How to achieve better development? -- editor [phenomenon] accelerate the iterative upgrading of vaccine R & D and production technology, promote the integration and innovation of biotechnology and additive manufacturing and other cutting-edge technologies, and expand the clinical application of advanced treatment technologies such as intelligent surgical robots... The "14th five year plan for Bioeconomic development" lists the "development of biomedicine for people's life and health" as one of the four key areas of Bioeconomics, It also proposes the development goal of significantly improving the social popularity of biological drugs and medical services during the "14th five year plan", which will bring new opportunities for promoting the innovation and upgrading of China's biological medicine health industry. [comments] the biomedical industry is a strategic emerging industry that has a bearing on the national economy and the people's livelihood and national security. It covers biotechnology industry, pharmaceutical industry, biomedical engineering industry and other aspects. In recent years, under the guidance of favorable policies, China's biomedical industry has entered the "fast lane" of development, and a series of new products and services have provided new assistance to protect people's lives and health. Looking at the industry, the R & D investment in the whole industry has increased significantly, thousands of new drugs have entered the clinic, hundreds of new drugs have carried out international multi center clinical trials, and more and more new drugs have been approved. From the perspective of enterprises, traditional pharmaceutical enterprises have accelerated the pace of transformation, constantly laid out the research and development of innovative drugs, and a large number of emerging biotechnology companies have been set up and grown rapidly. These innovative subjects are an important force to promote the innovation and development of biomedicine. The vigorous development of the biomedical industry is the result of the integration of biotechnology, information technology and other frontier technologies. Drug research and development is a high-risk, long-term and high-cost project. After many years of research and investment, it is possible to successfully develop a new drug. Basic research in life science and biotechnology is the driving force of medical innovation. Frontier emerging technologies such as artificial intelligence have unique advantages in reducing costs and increasing efficiency. For example, by simulating the drug characteristics of small molecule compounds, artificial intelligence technology can select the best candidate drugs for synthesis test in a short time, thus greatly improving the success rate of potential drugs and reducing the cost of drug discovery. It should also be noted that China's bio pharmaceutical industry still has shortcomings, and some fields are still at the stage of following up, and the original innovation ability is relatively weak. Biomedical technology has the characteristics of high knowledge, technology and capital intensity. To seize the opportunity of the era of the leapfrog development of the biological economy, it is necessary to increase the input of technology, capital, talents and other factors to continuously complement the development weaknesses. Internally, we should integrate resources and continue to increase investment in basic research, focusing on drugs, vaccines, advanced diagnosis and treatment technologies and equipment, biomedical materials, precision medicine, inspection and testing, and biological health care, so as to improve the original innovation ability and enhance the supply chain support level of high-end biomedical products and equipment; Looking outward, we should base ourselves on the domestic pharmaceutical market, attract global talents and other innovative elements to gather in China, and promote various foreign enterprises to set up R & D centers in China
Edit：qihang Responsible editor：xinglan
Source：People.cn
Special statement: if the pictures and texts reproduced or quoted on this site infringe your legitimate rights and interests, please contact this site, and this site will correct and delete them in time. For copyright issues and website cooperation, please contact through outlook new era email：lwxsd@liaowanghn.com
Recommended Reading Change it 
Home
